(Q33235110)

English

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 July 2017

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia (English)

1 reference

Europe PubMed Central

24 July 2017

0 references

0 references

biological psychiatry

1 reference

based on heuristic

inferred from title

Birte Yding Glenthøj

4

object named as

Birte Glenthoj

1 reference

Europe PubMed Central

24 July 2017

object named as

Peter Falkai

1

0 references

Hans-Jürgen Möller

6

object named as

Hans-Jürgen Möller

1 reference

Europe PubMed Central

24 July 2017

Jeffrey Lieberman

3

object named as

Jeffrey Lieberman

1 reference

Europe PubMed Central

24 July 2017

Wagner Farid Gattaz

5

object named as

Wagner F Gattaz

1 reference

Europe PubMed Central

24 July 2017

author name string

Thomas Wobrock

2

1 reference

Europe PubMed Central

24 July 2017

WFSBP Task Force on Treatment Guidelines for Schizophrenia

7

1 reference

Europe PubMed Central

24 July 2017

publication date

1 January 2006

1 reference

Europe PubMed Central

24 July 2017

World Journal of Biological Psychiatry

1 reference

Europe PubMed Central

24 July 2017

7

1 reference

Europe PubMed Central

24 July 2017

5-40

1 reference

Europe PubMed Central

24 July 2017

1

1 reference

Europe PubMed Central

24 July 2017

Systematic meta-review of depot antipsychotic drugs for people with schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Intramuscular preparations of antipsychotics: uses and relevance in clinical practice

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Atypical antipsychotic induced weight gain: pathophysiology and management

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Orlistat in the treatment of psychopharmacologically induced weight gain.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Interventions for Weight Gain in Adults Treated With Novel Antipsychotics

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Nizatidine for the treatment of patients with quetiapine-induced weight gain

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Impact of atypical antipsychotics on quality of life in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

A program for treating olanzapine-related weight gain

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

The predictive utility of expressed emotion in schizophrenia: an aggregate analysis

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Pharmacological management of first-episode schizophrenia and related nonaffective psychoses

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Influence of Family Life on the Course of Schizophrenic Disorders: A Replication

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Maintenance treatment for schizophrenia with quetiapine

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Treatment of negative symptoms

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Quetiapine. A review of its use in the management of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Repetitive transcranial magnetic stimulation in the treatment of chronic negative schizophrenia: a pilot study

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Overview: maintenance therapy in psychiatry: I. Schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Amantadine for weight gain associated with olanzapine treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Conventional antipsychotic medications for schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Clozapine eligibility among state hospital patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Effect of amantadine on weight gain during olanzapine treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Effect of baclofen on tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Neuroleptic withdrawal in schizophrenic patients. A review of the literature

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

A critique of the methods and conclusions in the patient outcome research team (PORT) report on psychological treatments for schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Weight decline in patients switching from olanzapine to quetiapine

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

High-frequency repetitive transcranial magnetic stimulation in schizophrenia: a combined treatment and neuroimaging study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Long-acting risperidone: a review of its use in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Gender differences in the effect of repetitive transcranial magnetic stimulation in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Amisulpride: progress and outcomes

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

The Effects of an Educational Intervention on Antipsychotic‐Induced Weight Gain

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

The Mount Sinai conference on the pharmacotherapy of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Physical health monitoring of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Transcranial magnetic stimulation for auditory hallucinations in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Management of the negative symptoms of schizophrenia: new treatment options

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Novel antipsychotics in the long-term treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Non-neuroleptic approaches to treating negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

High frequency repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Repetitive transcranial magnetic stimulation and electroconvulsive therapy in a patient with treatment-resistant schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Atypical antipsychotic weight gain: a major clinical challenge

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Clinical guidelines: developing guidelines

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

The onset and time course of response of negative symptoms to add-on fluvoxamine treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Antidepressant for substance-abusing schizophrenic patients: a minireview

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Clinical management of neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Cognitive behavior therapy for weight gain

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Systematic review of patient and nurse attitudes to depot antipsychotic medication.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Behavioural management of antipsychotic-induced weight gain: a review

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Baclofen in the treatment of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Relapse and Rehospitalization During Maintenance Treatment of Schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Fluoxetine as an Adjunct to Conventional Antipsychotic Treatment of Schizophrenia Patients with Residual Symptoms

1 reference

https://api.crossref.org/works/10.1080%2F15622970500483177

21 January 2018

Identifiers

10.1080/15622970500483177

1 reference

Europe PubMed Central

24 July 2017

1 reference

Europe PubMed Central

24 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33235110&oldid=1971422462"